Insight Molecular Diagnostics (IMDX) Consolidated Net Income: 2020-2025
Historic Consolidated Net Income for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$11.0 million.
- Insight Molecular Diagnostics' Consolidated Net Income rose 18.25% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 41.10%. This contributed to the annual value of -$61.0 million for FY2024, which is 1986.16% down from last year.
- Insight Molecular Diagnostics' Consolidated Net Income amounted to -$11.0 million in Q3 2025, which was down 12.25% from -$9.8 million recorded in Q2 2025.
- Over the past 5 years, Insight Molecular Diagnostics' Consolidated Net Income peaked at -$2.9 million during Q1 2023, and registered a low of -$35.7 million during Q4 2021.
- For the 3-year period, Insight Molecular Diagnostics' Consolidated Net Income averaged around -$11.1 million, with its median value being -$9.1 million (2024).
- Per our database at Business Quant, Insight Molecular Diagnostics' Consolidated Net Income plummeted by 438.57% in 2021 and then soared by 71.57% in 2023.
- Insight Molecular Diagnostics' Consolidated Net Income (Quarterly) stood at -$35.7 million in 2021, then increased by 7.65% to -$33.0 million in 2022, then spiked by 50.91% to -$16.2 million in 2023, then crashed by 107.84% to -$33.6 million in 2024, then increased by 18.25% to -$11.0 million in 2025.
- Its Consolidated Net Income was -$11.0 million in Q3 2025, compared to -$9.8 million in Q2 2025 and -$6.8 million in Q1 2025.